Mesoblast (MESO) - 2025 Q4 - Annual Report

mesoblast Exhibit 99.2 Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases Financial Results and Operational Update for the Full Year Ended June 30, 2025 August 2025 ASX: MSB; Nasdag: MESO CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS this presentation includes forward-looking statements that relate to future events or our future financial performance and involve rids, uncertainties and other factors tha cesults, levels of activity, performance or activements to differ materially ...